Brief: ClouDr Group Announces Launch Of Proprietary Product, Hetangjin Dapagliflozin Tablets
10/03/2024 23:23
March 11 (Reuters) - ClouDr Group Ltd 9955.HK :
* LAUNCH OF PROPRIETARY PRODUCT, HETANGJIN DAPAGLIFLOZIN
TABLETS
* TABLETS APPROVED FOR ENTRY INTO CHINESE MARKET
Further company coverage: 9955.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ClouDr
See all newsBrief: Cloudr Group Posts FY Revenue RMB 1,623.2 Million
Brief: Cloudr Says Co Expects FY Net Loss Between Rmb880 Million And Rmb980 Million
Brief: ClouDr Group Proposes Issue Of Convertible Bonds Under General Mandate
China's ClouDr rises to 4-month high on medical AI integration with DeepSeek-R1 model
Brief: Cloudr Announces Improvement Of Cloudr Brain Through Integration Of DeepSeek